La soluzione DiaSorin
DiaSorin offre soluzioni diagnostiche e di screening del sangue globali sia per l'epatite virale che per il rilevamento di retrovirus.
I saggi disponibili includono sia il formato ELISA, con il vantaggio del marchio Murex, sia la soluzione CLIA completamente automatizzata sui sistemi della famiglia LIAISON®.
La soluzione DiaSorin per l'epatite e i retrovirus garantisce un rilevamento e uno screening rapidi e accurati e i risultati diagnostici di alta qualità supportano anche le decisioni terapeutiche e il follow-up clinico dei pazienti infetti.
DiaSorin migliora la prevenzione e il trattamento delle epidemie sia di epatite che di retrovirus ottimizzando la valutazione virologica di prima linea con un pannello diagnostico CLIA completo e completamente automatizzato.
Facile, automatizzato ed efficiente
- Differenzia accuratamente le infezioni da epatite e retrovirus con il più ampio portafoglio di test immunologici in chemiluminescenza (CLIA)
- Migliora l'efficienza e i flussi di lavoro del laboratorio implementando una soluzione completa per l'epatite e i retrovirus sulla piattaforma LIAISON® XL completamente automatizzata
- Ottimizza il rilevamento delle infezioni trasmissibili per trasfusione grazie allo screening dei donatori di sangue per HBV, HCV, HIV, HTLV, Treponema e Chagas
- Seleziona in modo sicuro i donatori con il più ampio pannello convalidato per lo screening post-mortem di organi, tessuti e cellule, inclusi HBV, HCV, HDV, HEV, HIV e HTLV
- Consolidare il pannello CLIA per epatite e retrovirus completamente automatizzato all'interno del nostro portafoglio completo per la diagnosi delle malattie infettive
The LIAISON® XL Murex HBsAg Quant assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only. The LIAISON® HBsAg assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer only. The HBsAg Confirmatory Test is an in vitro neutralization assay for confirmation of the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma samples found repeatedly reactive for HBsAg by LIAISON® XL Murex HBsAg Quant or LIAISON® HBsAg. The LIAISON® XL MUREX HBsAg assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of Hepatitis B surface Antigen (HBsAg) in human serum and plasma samples included specimens collected post-mortem (non-heart beating). The assay is intended as an aid in the diagnosis of HBV infection in individuals with or without symptoms of hepatitis. It is also intended as a screening test for blood and hemocomponents donors as well as for organ, tissue and cells post-mortem donors. The test has to be performed on the LIAISON® XL analyzer only. The LIAISON® XL MUREX HBsAg assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of Hepatitis B surface Antigen (HBsAg) in human serum and plasma samples included specimens collected post-mortem (non-heart beating). The assay is intended as an aid in the diagnosis of HBV infection in individuals with or without symptoms of hepatitis. It is also intended as a screening test for blood and hemocomponents donors as well as for organ, tissue and cells post-mortem donors. The test has to be performed on the LIAISON® XL Analyzer only. The LIAISON® XL Anti-HBs II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family. The LIAISON® XL Anti-HBs II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family. The LIAISON® Anti-HBc assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of total antobodies to hepatitis B core antigen (anti-HBc) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family. The LIAISON® HBc IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of IgM immunoglobulim to hepatitis B core antigen (IgM anti-HBc) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family. The LIAISON® HBeAg assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of e antigen of hepatitis B virus (HBeAg) in human serum or plasma samples. HBeAg quantification may allow follow up of replicative activity/response to treatment (e.g. interferon) (20). The test has to be performed on the LIAISON® analyzer family. The LIAISON® Anti-HBe assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis B a antigen (anti-Bbe) in human serum or plasma samples. The test had to be perfomed on the LIAISON® analyzer family. The LIAISON® Anti-HAV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis A virus (anti-HAV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family. The LIAISON® HAV IgM assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of IgM immunoglobulin to hepatitis A virus (IgM anti-HAV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family. The LIAISON® XL Murex HCV Ab assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to hepatitis C virus (anti-HCV) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only. The LIAISON® XL Murex HIV Ab / Ag assay uses chemiluminescence immunoassay (CLIA) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (HIV-1) and specific antibodies to both human immunodeficiency virus type 1 (group M and group O) and/or human immunodeficiency virus type 2 (HIV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only. The LIAISON® XL Murex HIV Ab / Ag HT assay uses chemiluminescence immunoassay (CLIA) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (HIV-1) and specific antibodies to both human immunodeficiency virus type 1 (group M and group O) and/or human immunodeficiency virus type 2 (HIV-2) in human serum or plasma samples. The LIAISON® XL Murex recHTLV-I/II assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to Human T-cell Lymphotropic Virus (HTLV) type I and type II (anti-HTLV-I and anti-HTLV-II) in human serum or plasma samples. The LIAISON® XL Murex Anti-HDV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative detection of total antibodies to hepatitis D virus in human serum and plasma samples. The assay results, in conjunction with other laboratory results and clinical information, are intended to be used as an aid in the diagnosis of HDV infection and as a screening test for organ and tissue donors. Visit also http://hdv.diasorin.com/ The LIAISON® Murex Anti-HEV IgG assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of IgG antibodies to hepatitis E virus (Anti-HEV IgG) in human serum and plasma samples, including specimens collected post-mortem (non-heart beating). The LIAISON® Murex Anti-HEV IgM assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of IgM antibodies to hepatitis E virus (Anti-HEV IgM) in human serum and plasma samples, including specimens collected post-mortem (non-heart beating). Enzyme immunoassay for the detection of hepatitis B surface antigen in human serum or plasma. For the confirmation of the presence of hepatitis B surface antigen in human serum and plasma samples. To be used on serum or plasma samples found to be reactive in the Murex HBsAg Version 3 (9F80) assay. Enzyme immunoassay for the detection of antibodies to hepatitis B core antigen (anti-HBc) in human serum or plasma. An enzyme immunoassay for the detection of antibodies to hepatitis C virus (HCV) in human serum or plasma. Immunoassay for the simultaneous detection of hepatitis C (HCV) core antigen and anti-HCV antibodies in human serum or plasma. Enzyme immunoassay for improved detection of seroconversion to human immunodeficiency virus types 1 (HIV-1, HIV-1 group O) and detection of anti-HIV-2 antibodies in human serum or plasma. Enzyme immunoassay for the detection of antibodies to human immunodeficiency virus types 1 (HIV-1, HIV-1 group O) and 2 (HIV-2) in human serum or plasma. A qualitative enzyme immunoassay for the detection of antibodies against human T-lymphotropic virus types I and II (HTLV-I and HTLV-II) in human serum and plasma. Enzyme immunoassay for the detection of antibodies against Treponema pallidum in human serum and plasma.
The LIAISON® XL Murex HIV Ab / Ag HT assay is intended to be used as an aid in the diagnosis of HIV-1/HIV-2 infection and as a screening test for donated blood and plasma.
The test has to be performed on the LIAISON® XL Analyzer only.
The test has to be performed on the LIAISON® XL analyzer only.
The assay is intended as an aid in the diagnosis of HEV infection in individuals with or without symptoms of hepatitis and to evaluate the presence and the amount of Anti-HEV IgG. It is also intended as a screening test for post-mortem organ, tissue, and cell donors.
The assay has to be performed on the LIAISON® Analyzer family
The assay is intended as an aid in the diagnosis of HEV infection in individuals with or without symptoms of hepatitis. It is also intended as a screening test for post-mortem organ, tissue, and cells donors.
The assay has to be performed on the LIAISON® Analyzer family.
